Published in Dis Markers on April 05, 2015
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet (2005) 13.77
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2009) 12.66
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol (2003) 9.08
Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med (1995) 8.51
Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation (2003) 8.29
Protein arginine methylation in mammals: who, what, and why. Mol Cell (2009) 7.44
Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis (2009) 6.99
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Chronic kidney disease: effects on the cardiovascular system. Circulation (2007) 6.19
Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med (2008) 5.89
Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest (2005) 5.51
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99
Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem (1993) 4.90
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol (2003) 4.86
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A (1997) 4.20
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76
Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab (2006) 3.57
B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol (2006) 3.37
Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics (1997) 3.16
NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol (2007) 2.99
Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int (2007) 2.93
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet (2002) 2.92
Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med (2005) 2.90
Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol (2006) 2.89
B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation (2002) 2.85
GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res (2006) 2.85
The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res (2006) 2.85
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation (2012) 2.74
Adiponectin--a key adipokine in the metabolic syndrome. Diabetes Obes Metab (2006) 2.58
Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int (2013) 2.48
Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol (2002) 2.46
Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care (2003) 2.36
Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 2.34
Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun (2004) 2.32
Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension (2003) 2.32
Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation (2002) 2.30
Biomarkers in chronic kidney disease: a review. Kidney Int (2011) 2.25
Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis (2002) 2.25
Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest (2010) 2.23
Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis (2006) 2.09
Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol (2010) 2.06
NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant (2009) 2.06
Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem (2004) 2.01
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin. Diabetes (1998) 1.98
Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J (1999) 1.96
KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet (2003) 1.90
Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol (2005) 1.85
Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int (2007) 1.83
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant (2010) 1.78
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem (2013) 1.71
Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol (2006) 1.70
Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia (2005) 1.69
Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol (2002) 1.68
Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) (2007) 1.67
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. Clin Chem (2009) 1.64
The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant (2004) 1.62
Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant (2009) 1.51
Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail (2011) 1.48
Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population. Circ J (2010) 1.47
Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet (2002) 1.46
Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res (2004) 1.42
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J (2007) 1.40
A basic science view of acute kidney injury biomarkers. Nephrol Dial Transplant (2014) 1.33
Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res (2009) 1.31
B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med (2003) 1.31
Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res (2009) 1.31
Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab (1997) 1.28
Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis (2009) 1.28
Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem (2004) 1.25
Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci (2011) 1.25
Regulation of leptin production in humans. J Nutr (2000) 1.23
Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation (2000) 1.22
Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol (2012) 1.20
Association between renal insufficiency and malnutrition in older adults: results from the NHANES III. Kidney Int (2001) 1.20
Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) (2005) 1.16
N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol (2006) 1.14
Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int (2012) 1.13
Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res (1995) 1.13
Reduced Klotho is associated with the presence and severity of coronary artery disease. Heart (2013) 1.13
Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol (2013) 1.12
Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes (Lond) (2005) 1.12
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol (2013) 1.10